A Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of BHV-3500 in Healthy Volunteers

Trial Profile

A Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of BHV-3500 in Healthy Volunteers

Planning
Phase of Trial: Phase I

Latest Information Update: 12 Mar 2018

At a glance

  • Drugs BHV-3500 (Primary)
  • Indications Migraine
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Mar 2018 According to a Biohaven Pharmaceutical Holding Company media release, the trial is scheduled to begin in the first half of 2018.
    • 06 Mar 2018 According to a Biohaven Pharmaceutical Holding Company Ltd media release, the company remains on track to submit an investigational new drug application (IND) in first half of 2018 for BHV-3500 for the acute treatment and prevention of migraine and expects to conduct this trial in the second half of 2018.
    • 26 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top